Kristin Brooks02.09.21
Pfizer
4Q Revenues: $11.7 billion (+12%)
4Q Earnings: $594 million (loss of $337 million 4Q20)
FY Revenues: $41.9 billion (+2%)
FY Earnings: $9.6 billion (-41%)
Comments: Growth primarily driven by strong performances from Vyndaqel/Vyndamax, Eliquis, Oncology Biosimilars, Ibrance, Prevenar 13 Outside of the U.S., Inlyta, Xeljanz and Xtandi.
Vyndaqel/Vyndamax sales were $429 million in the quarter, up 96%. Eliquis alliance revenues and direct sales were $1.3 billion, up 15%. Ibrance sales were $1.4 billion, up 12%. Prevenar 13 sales were $1.8 billion, up 11%. Inlyta sales were up 42% to $228 million. Xeljanz sales were up 15% to $696 million. Xtandi alliance revenues were $283 million, up 16%. BNT162b2, which was granted an emergency use authorization (EUA) in the U.S. in December 2020, contributed $154 million in sales in the quarter. Biosimilar sales were up 88% to $525 million, primarily driven by recent oncology biosimilar launches of Ruxience (rituximab), Zirabev (bevacizumab) and Trazimera (trastuzumab). R&D expenses were up 21% to $3.4 billion in the quarter. The Upjohn Business is now accounted for as a discontinued operation.
4Q Revenues: $11.7 billion (+12%)
4Q Earnings: $594 million (loss of $337 million 4Q20)
FY Revenues: $41.9 billion (+2%)
FY Earnings: $9.6 billion (-41%)
Comments: Growth primarily driven by strong performances from Vyndaqel/Vyndamax, Eliquis, Oncology Biosimilars, Ibrance, Prevenar 13 Outside of the U.S., Inlyta, Xeljanz and Xtandi.
Vyndaqel/Vyndamax sales were $429 million in the quarter, up 96%. Eliquis alliance revenues and direct sales were $1.3 billion, up 15%. Ibrance sales were $1.4 billion, up 12%. Prevenar 13 sales were $1.8 billion, up 11%. Inlyta sales were up 42% to $228 million. Xeljanz sales were up 15% to $696 million. Xtandi alliance revenues were $283 million, up 16%. BNT162b2, which was granted an emergency use authorization (EUA) in the U.S. in December 2020, contributed $154 million in sales in the quarter. Biosimilar sales were up 88% to $525 million, primarily driven by recent oncology biosimilar launches of Ruxience (rituximab), Zirabev (bevacizumab) and Trazimera (trastuzumab). R&D expenses were up 21% to $3.4 billion in the quarter. The Upjohn Business is now accounted for as a discontinued operation.
